Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

By Dr. Matthew Watson

Oslo, January 31, 2025: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today.

Continued here:
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

Rakovina Therapeutics Announces Listing on Frankfurt Stock Exchange - January 31st, 2025
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board - January 31st, 2025
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - January 31st, 2025
Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - January 31st, 2025
Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference - January 31st, 2025
Avid Stockholders Approve Transaction with GHO and Ampersand - January 31st, 2025
Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025 - January 31st, 2025
Portage Biotech Announces Completion of $2.15 Million Private Financing - January 31st, 2025
Diag-Nose.io, Graduate of Stanford EENT Innovation, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision... - January 31st, 2025
Diag-Nose.io Opens Houston Office following oversubscribed $2M Seed Round to Measure Respiratory Treatment Success Using Proteomics & AI - January 31st, 2025
Diag-Nose.io Expands to Bethlehem, PA, Following Oversubscribed $2M Seed Round Funding to Revolutionize Respiratory Diagnostics - January 31st, 2025
Diag-Nose.io, Graduate of CDL-Seattle, Closes Oversubscribed $2M Seed Round to Transform Respiratory Care with AI-Driven Precision Medicine - January 31st, 2025
Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics Technology Platform - January 31st, 2025
BioSyent Declares First Quarter 2025 Dividend - January 31st, 2025
Tarsus to Participate in Upcoming Investor Conferences - January 31st, 2025
Ryoncil® Commercial Launch Update and Product Pipeline - January 31st, 2025
Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - January 31st, 2025
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - January 31st, 2025
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for... - January 31st, 2025
Shuttle Pharma Reaches Milestone in Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma - January 22nd, 2025
Nacuity Pharmaceuticals Granted U.S. FDA Fast Track Designation for NPI-001 (N-acetylcysteine amide) Tablets for the Treatment of Retinitis Pigmentosa - January 22nd, 2025
Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology - January 22nd, 2025
Welcoming Victor Bornsztejn as Senior Vice President of Commercial - January 22nd, 2025
Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization... - January 22nd, 2025
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - January 22nd, 2025
Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31,... - January 22nd, 2025
RS BioTherapeutics Announces Positive Anti-Inflammatory and Anti-Fibrotic Effects of Lead Compound in Human Lung Tissue - January 22nd, 2025
Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) - January 22nd, 2025
Pharming Group to convene Extraordinary General Meeting of Shareholders - January 22nd, 2025
BioAdaptives Announces FINRA Approval of a Dividend for Common Stock Shareholders - January 22nd, 2025
Sanara MedTech Inc. Expands Executive Leadership Team with New Appointments - January 22nd, 2025
Sanara MedTech Inc. Announces Exclusive License and Distribution Agreement with, and Minority Investment in, Biomimetic Innovations Ltd - January 22nd, 2025
Sanara MedTech Inc. Reports Unaudited Preliminary Results for the Fourth Quarter and Full Year 2024 - January 22nd, 2025
NurExone Secures C$1.2 Million through Warrant Exercises and Completion of Private Placement and Appoints New R&D Director - January 22nd, 2025
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO... - January 22nd, 2025
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in... - January 22nd, 2025
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible... - January 22nd, 2025
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI - January 22nd, 2025
Roche receives FDA clearance with CLIA waiver for cobas® liat molecular tests to diagnose sexually transmitted infections at the point of care - January 22nd, 2025
Apellis Highlights Commercial Growth and Strategic Priorities at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
VIVUS Shares Progress on Pipeline and Key Program Milestones During the 43rd Annual J.P. Morgan Healthcare Conference 2025 - January 14th, 2025
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities - January 14th, 2025
Artelo Biosciences Announces Successful Completion of First Cohort in a Phase 1 Study of ART26.12 - January 14th, 2025
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones - January 14th, 2025
ProMIS Neurosciences Issues Letter to Shareholders - January 14th, 2025
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones - January 14th, 2025
OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer - January 14th, 2025
Correction: GUERBET : Financial agenda for 2025 - January 14th, 2025
Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without... - January 14th, 2025
Telix Presentation to the 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference - January 14th, 2025
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - January 14th, 2025
FDA Accepts LEQEMBI® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s... - January 14th, 2025
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial - January 14th, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC - January 14th, 2025
Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference - January 14th, 2025
Idorsia publishes an invitation to a bondholder meeting - January 14th, 2025
Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease - January 14th, 2025
Santhera Receives Positive Recommendation from Scottish Medicines Consortium for the Use of AGAMREE® (Vamorolone) in Duchenne Muscular Dystrophy... - January 14th, 2025
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning - January 5th, 2025
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab - January 5th, 2025
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin® - January 5th, 2025
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - January 5th, 2025
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8 - January 5th, 2025
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar - January 5th, 2025
Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc. - January 5th, 2025
VALNEVA Declaration of shares and voting rights: December 31, 2024 - January 5th, 2025
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference - January 5th, 2025
Procaps Group Receives Additional Delinquency Letter - January 5th, 2025
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - January 5th, 2025
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025 - January 5th, 2025
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week - January 5th, 2025
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 5th, 2025
BriaCell Announces Proposed Effective Date of Share Consolidation - January 5th, 2025
PharmaTher Announces Grant of Stock Options - January 5th, 2025
Oculis Publishes Notification of Major Changes in Voting Rights - January 5th, 2025
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - December 27th, 2024

Global News Feed commento

Comments Off | data

January 31st, 2025

About... Dr. Matthew Watson

This author published 6012 posts in this site.

Comments are closed.

Previous post - Next post

Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update

By Dr. Matthew Watson

About... Dr. Matthew Watson

Share

Comments are closed.

Categories

Archives

Recommended Sites